Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spruce Biosciences (SPRB) EBITDA (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed EBITDA for 4 consecutive years, with -$11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 52.88% to -$11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$36.5 million, a 31.15% increase, with the full-year FY2025 number at -$36.5 million, up 31.15% from a year prior.
  • EBITDA was -$11.1 million for Q4 2025 at Spruce Biosciences, down from -$8.2 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.7 million in Q2 2025 to a low of -$23.6 million in Q4 2024.
  • A 4-year average of -$11.5 million and a median of -$11.5 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: crashed 136.85% in 2024, then skyrocketed 70.68% in 2025.
  • Spruce Biosciences' EBITDA stood at -$10.8 million in 2022, then rose by 8.15% to -$9.9 million in 2023, then crashed by 136.85% to -$23.6 million in 2024, then skyrocketed by 52.88% to -$11.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's EBITDA are -$11.1 million (Q4 2025), -$8.2 million (Q3 2025), and -$2.7 million (Q2 2025).